Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Wells G, Coyle D, Cameron C, et al. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Apr 9.
Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet].
Show details7.3 Literature Search Strategy
7.5 SIGN50 Quality Assessment Instrument for RCT
7.6 Risk of Bias Assessment Tool
7.7 Risk Estimates Reported and Computed
7.8 Included and Excluded Studies
7.9 Patient Inclusion and Exclusion Criteria from Included Studies
7.11 Random Effects MTC Network Meta-analysis Results versus adjusted-dose warfarin
- APPENDICES - Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagu...APPENDICES - Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Your browsing activity is empty.
Activity recording is turned off.
See more...